STOCK TITAN

namsw - namsw STOCK NEWS

Welcome to our dedicated news page for namsw (Ticker: namsw), a resource for investors and traders seeking the latest updates and insights on namsw.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect namsw's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of namsw's position in the market.

Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces positive clinical trial progress, upcoming milestones, and financial results for 2023. They reported encouraging Phase 2 trial data for obicetrapib, with plans for Phase 3 trials and a pivotal trial for a fixed-dose combination. The company completed a successful public offering, raising $202 million. Despite a decrease in cash and revenue, R&D and SG&A expenses increased, resulting in a higher net loss for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
earnings
-
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces positive clinical trial progress, upcoming milestones, and financial results for 2023. They reported encouraging Phase 2 trial data for obicetrapib, with plans for Phase 3 trials and a pivotal trial for a fixed-dose combination. The company completed a successful public offering, raising $202 million. Despite a decrease in cash and revenue, R&D and SG&A expenses increased, resulting in a higher net loss for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
earnings
-
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) announces participation in three upcoming investor conferences to present their late-stage, clinical biopharmaceutical developments for cardiovascular disease. Live webcasts and archived replays will be available for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
conferences
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) announces participation in three upcoming investor conferences to present their late-stage, clinical biopharmaceutical developments for cardiovascular disease. Live webcasts and archived replays will be available for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.13%
Tags
conferences
-
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces the pricing of a public offering, expecting to raise approximately $175.3 million to fund the development of oral, non-statin medicines for patients at risk of cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
offering
-
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces the pricing of a public offering, expecting to raise approximately $175.3 million to fund the development of oral, non-statin medicines for patients at risk of cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
offering
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces a public offering of ordinary shares and pre-funded warrants. The underwritten public offering aims to raise capital for the late-stage clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
offering
-
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces a public offering of ordinary shares and pre-funded warrants. The underwritten public offering aims to raise capital for the late-stage clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
offering
-
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announced that CEO Michael Davidson and CFO Ian Somaiya will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024. The company is a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The webcast will be available through the investor relations section of the NewAmsterdam Pharma website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.01%
Tags
conferences
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announced that CEO Michael Davidson and CFO Ian Somaiya will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024. The company is a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The webcast will be available through the investor relations section of the NewAmsterdam Pharma website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
namsw

Nasdaq:NAMSW

NAMSW Rankings

NAMSW Stock Data